> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Outlook Wins FDA Appeal After 3 Complete Responses
- URL: https://www.fdaweb.com/outlook-wins-fda-appeal-after-3-complete-responses/
- Published: 2026-05-26T12:00:00.000Z
- Updated: 2026-09-14T13:39:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161198

Outlook Therapeutics has won an appeal with FDA over its BLA for ONS-5010/Lytenava (bevacizumab-vikg), clearing a potential path toward U.S. approval of the investigational wet age-related macular degeneration treatment. The agency granted the company’s appeal following a Formal Dispute Resolution process with the agency’s Office of New Drugs, according to the company. Outlook said it now plans to resubmit its BLA next month.

The dispute stemmed from a complete response letter (CRL) issued by FDA 12/2025 concerning the company’s application for the ophthalmic bevacizumab formulation for neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a leading cause of vision loss among older adults and is commonly treated with anti-VEGF injections designed to reduce abnormal blood vessel growth and leakage in the retina.

The company has been rejected three times by FDA reviewers. An 8/2025 CRL cited insufficient evidence of effectiveness. The agency said it could not approve the application in its current form because the pivotal NORSE EIGHT trial failed to meet its primary efficacy endpoint, according to the company. While FDA acknowledged that the earlier NORSE TWO study did demonstrate effectiveness, regulators recommended in the letter that the company provide confirmatory evidence before the drug could be considered for approval. In 8/2023, FDA issued the original BLA a complete response letter that cited several chemistry, manufacturing and control issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence, according to the company.

According to Outlook, FDA has now concluded that “substantial evidence of effectiveness” had been established for Lytenava based on results from the company’s NORSE TWO clinical trial, together with confirmatory evidence from the NORSE EIGHT study and additional mechanistic and pharmacodynamic data.

The company said FDA directed the Division of Ophthalmology and Office of Specialty Medicine to work with Outlook on final product labeling. Outlook added that the resubmission is expected to be treated as a Class 1 resubmission, which typically carries a two-month review timeline after FDA acceptance.

If approved, ONS-5010/LYTENAVA would become the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases supported by an FDA-approved manufacturing process and labeling, the company said. Bevacizumab, widely known in oncology under Roche’s Avastin brand, has long been used off-label by ophthalmologists to treat retinal diseases including wet AMD because of its lower cost relative to other anti-VEGF therapies. Outlook has been seeking approval for a specifically formulated ophthalmic version manufactured for intravitreal use.